Want access to unlimited case records and advanced research tools? Create your free CasePortal account now. No credit card required to register.
Try CasePortal for FreeJ. Connolly finds that claim 5 of U.S. Patent No. 6,911,46, which concerns an epilepsy treatment, is not invalid due to inadequate written description because drug makers seeking to market generic tablets of Briviact failed to prove a skilled artisan would obviously alter levetiracetam in such a way that it would yield a successful anti-seizure compound.
To read this case, start your 14-day free trial.
Request a free trial account to get access to more case data, documents, and features.
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.